BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Genexine to test toxicity of immunotherapeutic drug candidate for intranasal administration

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : August 18, 2020, 15:09 | Updated : August 18, 2020, 15:09
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Genexine]

SEOUL -- Genexine, a clinical-stage biotechnology company involved in a state-commissioned research consortium to develop a DNA vaccine material for COVID-19, will conduct a pre-clinical test to confirm the toxicity of its immunotherapeutic drug candidate, GX-I7, by spraying it to the nasal cavity.

According to Genexine, the intranasal administration method prevents virus infection for 5 to 35 days by increasing lymphocytes that control the immune system in the airway mucosa area where GX-I7 is applied. The study will be done with the support of the Research Investment for Global Health Technology (RIGHT) Fund, which is a funding agency dedicated to supporting global health research and development.

Genexine and its U.S. co-developer NeoImmuneTech, a clinical-stage T cell-focused bio company, have secured approval from the Food and Drug Administration to conduct Phase 1 clinical trials for GX-I7 to see if it is effective in the treatment of COVID-19. Genexine has said that GX-I7 showed good efficacy when used in combination with a variety of immunotherapeutic agents.

South Korea has unveiled a roadmap for the treatment of COVID-19 to develop plasma treatment by the year's end as well as antibody treatment and vaccines next year.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .LSK Global PS to conduct third-stage clinical test of Chinese vaccine in Bangladesh.
    LSK Global PS to conduct third-stage clinical test of Chines…
  • .GC Pharma shares up on expected consignment production deal with Moderna .
    GC Pharma shares up on expected consignment production deal …
  • .S. Korean regulators start review on AstraZeneca vaccine for quick use in February .
    S. Korean regulators start review on AstraZeneca vaccine for…
  • .SK Bioscience embarks on clinical test of COVID-19 vaccine candidate NBP2001 .
    SK Bioscience embarks on clinical test of COVID-19 vaccine c…
  • .[INTERVIEW] Sugentech predicts modest sales after development of vaccines .
    [INTERVIEW] Sugentech predicts modest sales after developmen…

Real Time Photo News

  • .Singer IU drops teaser image for upcoming full album.

    Singer IU drops teaser image for upcoming full album

  • .Cube Entertainment partners with web comics company to create online video content.

    Cube Entertainment partners with web comics company to create online video content

  • .Sci-fi film starring Song Joong-ki to be reelased on Netflix in February.

    Sci-fi film starring Song Joong-ki to be reelased on Netflix in February

  • .Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series Criminal Justice.

    Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series 'Criminal Justice'

  • .CJ ENM partners with NCSoft to roll out new digital content for global market.

    CJ ENM partners with NCSoft to roll out new digital content for global market

Latest News

more+

  • EOFlow to raise new capital for development of wearable artificial pancreas and new businesses
  • En+ Group's metal business partners with Henan Mingtai to deliver low-carbon aluminium products
  • New negative-pressure ambulances to be used by S. Korean fire stations
  • Doosan Mobility's hydrogen drones to be used for safe voyage solutions
  • Samsung supports smart production of COVID-19 vaccine syringes
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view